

FOR IMMEDIATE RELEASE**Montreal, Quebec, Canada- September 25, 2007**

Supratek Pharma Inc. announced today the submission of an Investigational New Drug (IND) application and a request for Special Protocol Assessment (SPA) to the Division of Drug Oncology Products of U.S. Food and Drug Administration (FDA) for a new anticancer drug known as SP1049C.

The IND proposes a randomized Phase III pivotal clinical trial that will compare SP1049C plus Best Supportive Care (BSC) versus BSC alone for the treatment of patients with advanced upper gastrointestinal tract adenocarcinoma (including esophageal, gastroesophageal junction and gastric tumors) who have failed adjuvant or 1st or 2nd line chemotherapy. Supratek Pharma is Sponsor of the IND and will direct the clinical development program. Through the FDA's SPA process, Supratek Pharma expects to reach an agreement with FDA on overall protocol design, primary efficacy endpoints and data analysis as well as aspects of expected labeling if the data from the pivotal trial are supportive and is approved by the FDA.

“Supratek Pharma has pursued this project for a number of years and we are very pleased with our results”, said Dr. Christopher E. Newman, Vice-President and Chief Medical Officer of Supratek Pharma “the recent SP1049C Phase II trial in patients with metastatic adenocarcinoma of the esophagus and gastroesophageal junction has shown response rates and patient median survival that were better than most active single chemotherapeutic agents in this usually chemotherapy resistant cancer,”

“Metastatic and drug resistant cancers are responsible for most cancer deaths. We are very pleased with the progress of SP1049C, which is a novel anthracycline that has shown high activity in drug resistant tumors where conventional anthracyclines are not active” said Oleg Romar, President and CEO of Supratek. “Patients with metastatic disease and those that have failed first line therapy are in desperate need of a new anticancer weapon. If SP1049C achieves its end-point of overall survival benefit, patients with many untreatable or difficult to treat cancers will be given new hope. “

About SP1049C

Supratek's lead anticancer drug candidate, SP1049C, is based on Biotransport™ technology. This drug is a proprietary composition of poloxamers with one of the most potent cytotoxic drugs, doxorubicin. Doxorubicin is among the most widely utilized anticancer drugs but is limited in its clinical use by inherent or induced drug resistance. While SP1049C retains the fundamental therapeutic characteristics of the doxorubicin, it has been shown to have much higher efficacy and a novel mechanism of action against tumors in which the original drug is inactive. SP1049C has received an Orphan Drug designation from FDA for the treatment of esophageal carcinoma.

About Supratek Pharma Inc.

Supratek Pharma is a pharmaceutical company focused on the treatment of drug resistant and metastatic cancers. The company has eight proprietary products in its pipeline. In addition to its lead compound, SP1049C, SP-MET-X1 is its second most advanced product. It is based on the Company's potential breakthrough discovery of a biochemical pathway and target consistently involved in metastasis formation and cancer progression. SP-MET-X1, the first drug developed in this new therapeutic class, is a novel use of an existing non-cancer drug that is specific to the new target. The Company is planning a Phase I/II proof-of-concept clinical trial.

For further information:

Oleg Romar
President and Chief Executive Officer
Supratek Pharma Inc.
Phone: (514) 849-6094 ext. 102
e-mail: oleg.romar@supratek.com